tiprankstipranks
Albireo Pharma downgraded to Neutral from Buy at Guggenheim
The Fly

Albireo Pharma downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Seamus Fernandez downgraded Albireo Pharma (ALBO) to Neutral from Buy after the company agreed to be acquired by Ipsen (IPSEY) for $42 per share in cash plus one contingent value right worth $10 per share payable upon the FDA approval of Bylvay in the biliary atresia indication.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ALBO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles